2023-09-28 14:46:10 +00:00
|
|
|
abstract: 'Despite of the rapid development of the vaccines against the severe
|
|
|
|
|
|
|
|
|
|
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take
|
|
|
|
|
|
|
|
|
|
several months to have enough doses and the proper infrastructure to
|
|
|
|
|
|
|
|
|
|
vaccinate a good proportion of the world population. In this interim,
|
|
|
|
|
|
|
|
|
|
the accessibility to the Bacille Calmette-Guerin (BCG) may mitigate the
|
|
|
|
|
|
|
|
|
|
pandemic impact in some countries and the BCG vaccine offers significant
|
|
|
|
|
|
|
|
|
|
advantages and flexibility in the way clinical vaccines are
|
|
|
|
|
|
|
|
|
|
administered. BCG vaccination is a highly cost-effective intervention
|
|
|
|
|
|
|
|
|
|
against tuberculosis (TB) and many low-and lower-middle-income countries
|
|
|
|
|
|
|
|
|
|
would likely have the infrastructure, and health care personnel
|
|
|
|
|
|
|
|
|
|
sufficiently familiar with the conventional TB vaccine to mount
|
|
|
|
|
|
|
|
|
|
full-scale efforts to administer novel BCG-based vaccine for COVID-19.
|
|
|
|
|
|
|
|
|
|
This suggests the potential for BCG to overcome future barriers to
|
|
|
|
|
|
|
|
|
|
vaccine roll-out in the countries where health systems are fragile and
|
|
|
|
|
|
|
|
|
|
where the effects of this new coronavirus could be catastrophic. Many
|
|
|
|
|
|
|
|
|
|
studies have reported cross-protective effects of the BCG vaccine toward
|
|
|
|
|
|
|
|
|
|
non-tuberculosis related diseases. Mechanistically, this
|
|
|
|
|
|
|
|
|
|
cross-protective effect of the BCG vaccine can be explained, in part, by
|
|
|
|
|
|
|
|
|
|
trained immunity, a recently discovered program of innate immune memory,
|
|
|
|
|
|
|
|
|
|
which is characterized by non-permanent epigenetic reprogramming of
|
|
|
|
|
|
|
|
|
|
macrophages that leads to increased inflammatory cytokine production and
|
|
|
|
|
|
|
|
|
|
consequently potent immune responses. In this review, we summarize
|
|
|
|
|
|
|
|
|
|
recent work highlighting the potential use of BCG for the treatment
|
|
|
|
|
|
|
|
|
|
respiratory infectious diseases and ongoing SARS-CoV-2 clinical trials.
|
|
|
|
|
|
|
|
|
|
In situations where no other specific prophylactic tools are available,
|
|
|
|
|
|
|
|
|
|
the BCG vaccine could be used as a potential adjuvant, to decrease
|
|
|
|
|
|
|
|
|
|
sickness of SARS-CoV-2 infection and/or to mitigate the effects of
|
|
|
|
|
|
|
|
|
|
concurrent respiratory infections.'
|
|
|
|
|
affiliation: 'Ochando, J (Corresponding Author), Inst Salud Carlos III, Dept Immunol,
|
|
|
|
|
Transplant Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
|
|
|
|
|
|
|
|
|
|
Ochando, J (Corresponding Author), Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York,
|
|
|
|
|
NY 10029 USA.
|
|
|
|
|
|
|
|
|
|
Gonzalez-Perez, Maria; Ochando, Jordi, Inst Salud Carlos III, Dept Immunol, Transplant
|
|
|
|
|
Immunol Unit, Natl Ctr Microbiol, Madrid, Spain.
|
|
|
|
|
|
|
|
|
|
Sanchez-Tarjuelo, Rodrigo; Ochando, Jordi, Icahn Sch Med Mt Sinai, Dept Oncol Sci,
|
|
|
|
|
New York, NY 10029 USA.
|
|
|
|
|
|
|
|
|
|
Shor, Boris, Manhattan BioSolut, New York, NY USA.
|
|
|
|
|
|
|
|
|
|
Nistal-Villan, Estanislao, Univ San Pablo Ctr Estudios Univ CEU, Fac Farm, Microbiol
|
|
|
|
|
Sect, Dept Ciencias Farmaceut \& Salud, Madrid, Spain.
|
|
|
|
|
|
|
|
|
|
Nistal-Villan, Estanislao, Univ San Pablo CEU, Inst Med Mol Aplicada IMMA, Fac Med,
|
|
|
|
|
Madrid, Spain.'
|
|
|
|
|
article-number: '632478'
|
|
|
|
|
author: Gonzalez-Perez, Maria and Sanchez-Tarjuelo, Rodrigo and Shor, Boris and Nistal-Villan,
|
|
|
|
|
Estanislao and Ochando, Jordi
|
|
|
|
|
author-email: Jordi.ochando@mssm.edu.edu
|
|
|
|
|
author_list:
|
|
|
|
|
- family: Gonzalez-Perez
|
|
|
|
|
given: Maria
|
|
|
|
|
- family: Sanchez-Tarjuelo
|
|
|
|
|
given: Rodrigo
|
|
|
|
|
- family: Shor
|
|
|
|
|
given: Boris
|
|
|
|
|
- family: Nistal-Villan
|
|
|
|
|
given: Estanislao
|
|
|
|
|
- family: Ochando
|
|
|
|
|
given: Jordi
|
|
|
|
|
da: '2023-09-28'
|
|
|
|
|
doi: 10.3389/fimmu.2021.632478
|
|
|
|
|
files: []
|
|
|
|
|
issn: 1664-3224
|
|
|
|
|
journal: FRONTIERS IN IMMUNOLOGY
|
|
|
|
|
keywords: 'Bacille Calmette-Guerin; SARS-CoV-2; vaccination; trained immunity;
|
|
|
|
|
|
|
|
|
|
cross-protection'
|
|
|
|
|
keywords-plus: 'BACILLUS-CALMETTE-GUERIN; RESPIRATORY SYNCYTIAL VIRUS; TRAINED IMMUNITY;
|
|
|
|
|
|
|
|
|
|
NONSPECIFIC PROTECTION; GUINEA-BISSAU; RECOMBINANT; INFECTION;
|
|
|
|
|
|
|
|
|
|
RESPONSES; EFFICACY; MEMORY'
|
|
|
|
|
language: English
|
|
|
|
|
month: MAR 8
|
|
|
|
|
number-of-cited-references: '68'
|
|
|
|
|
orcid-numbers: 'Ochando, jordi/0000-0001-7037-1681
|
|
|
|
|
|
|
|
|
|
Nistal-Villan, Estanislao/0000-0003-2458-8833
|
|
|
|
|
|
|
|
|
|
Gonzalez Perez, Maria/0000-0003-0838-4734
|
|
|
|
|
|
|
|
|
|
Sanchez Tarjuelo, Rodrigo/0000-0002-3252-2722'
|
|
|
|
|
papis_id: 409cc5f0651b9c4f28972a54ac5577cc
|
|
|
|
|
ref: Gonzalezperez2021bcgvaccine
|
|
|
|
|
researcherid-numbers: 'Ochando, jordi/ABE-2358-2020
|
|
|
|
|
|
|
|
|
|
Nistal-Villan, Estanislao/GWM-7994-2022
|
|
|
|
|
|
|
|
|
|
Nistal-Villan, Estanislao/C-6122-2015
|
|
|
|
|
|
|
|
|
|
'
|
|
|
|
|
tags:
|
|
|
|
|
- review
|
|
|
|
|
times-cited: '43'
|
|
|
|
|
title: 'The BCG Vaccine for COVID-19: First Verdict and Future Directions'
|
2023-10-01 08:15:07 +00:00
|
|
|
type: article
|
2023-09-28 14:46:10 +00:00
|
|
|
unique-id: WOS:000630922700001
|
|
|
|
|
usage-count-last-180-days: '0'
|
|
|
|
|
usage-count-since-2013: '4'
|
|
|
|
|
volume: '12'
|
|
|
|
|
web-of-science-categories: Immunology
|
|
|
|
|
year: '2021'
|
